Compare Okta, Inc. (OKTA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs TG Therapeutics Inc — how do they compare? Okta, Inc. trades at $232.13 (market cap $38.50B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Okta, Inc. is far larger — about 4.7× TG Therapeutics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and TG Therapeutics Inc for 16 Days on average.
| OKTA | TGTX | |
|---|---|---|
Market Cap | $38.50B | $8.16B |
Volume | 2,479,621 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $220.21 | $59.06 |
52-Week Low | $62.93 | $26.94 |
Typical Hold Time | 44 Days | 16 Days |
Enterprise Value | $36.25B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages and strong analyst support (73.58% buy ratings). The company reported a net income of $28 million in 2025, marking a return to profitability after losses in prior years, with revenue growing to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
The outlook is positive due to earnings beats, AI-driven growth potential, and improving cash flow, but risks include high valuation multiples (P/E of 132.66) and competitive pressures in cybersecurity. The stock trades above the consensus price target of $201.30, suggesting near-term consolidation may occur despite long-term growth prospects.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
